Test Price
900 AED✅ Home Collection Available
Cytomegalovirus Interferon Gamma Release Assay (CMV IGRA) Test in UAE
Executive Summary & Core Metrics
The Cytomegalovirus Interferon Gamma Release Assay (CMV IGRA) is a definitive functional cellular immunity assay for CMV risk stratification in transplant candidates, oncology patients, and immunocompromised individuals. Processed at DNA Labs UAE under DHA facility license 1143 with next-day reporting, this test delivers 99.9% diagnostic sensitivity via ISO 9001:2015 accredited methodology (Cert: INT/EGQ/2509DA/3139). Premium logistics include VIP mobile phlebotomy with temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM, followed by telephonic post-test clinical guidance from DHA-licensed specialists. Insurance verification and appointment scheduling are available via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The CMV IGRA is a specialized enzyme immunoassay (ELISA) that quantifies T-cell mediated immune response to CMV-specific antigens, providing functional immunological data critical for pre-transplant risk assessment and post-transplant monitoring in solid organ and hematopoietic stem cell transplant recipients. Unlike standard serology that only detects past antibody exposure, this assay reveals whether the cellular immune system is actively capable of controlling CMV reactivation.
| Parameter | DNA Labs UAE CMV IGRA | Standard CMV Serology (IgG/IgM) |
|---|---|---|
| Methodology | Enzyme Immunoassay (ELISA) — Functional T-Cell Response | Indirect Serology — Antibody Detection Only |
| Diagnostic Precision | 99.9% Sensitivity (ISO 9001:2015 Validated) | Variable; limited functional immune insight |
| Turnaround Time | Next-Day Reporting (Mon/Thu by 9 AM) | 2–5 Business Days (typical) |
| Clinical Applicability | Transplant Risk Stratification, Immunocompromised Monitoring | Past Exposure Screening; limited transplant utility |
| Sample Collection | VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (8 AM – 11 PM) | Clinic-based draw only |
Physician Insight & Safety Protocols
Dr. Ajay Singh (DHA License: 36234132) notes: "The CMV IGRA test offers critical functional immune insight for managing immunocompromised patients, particularly in the transplant setting. Interpreting the quantitative interferon-gamma result requires full clinical correlation including immunosuppressant regimen, viral load trends, and graft function. A negative IGRA result in a pre-transplant candidate indicates elevated risk for CMV reactivation, while a positive result reflects detectable cellular immunity. Always discuss laboratory findings with your treating specialist before making any therapeutic adjustments."
⚠ Critical Medication Advisory
Never discontinue or alter prescribed immunosuppressive agents, antiviral therapy, or any other medication based solely on CMV IGRA results. This assay is a monitoring adjunct within a comprehensive clinical management strategy, not a standalone directive. All therapeutic decisions require joint consultation with your transplant physician or oncologist.
Safety Advisory — Exclusion Criteria & Emergency Red Flags
Exclusion Criteria (Home Collection):
- Active severe infection with fever exceeding 38.5°C at time of collection.
- Administration of any live attenuated vaccine within the preceding 14 days.
- Known hypersensitivity to heparin (sodium/lithium heparin tube used); alternative collection consultation required.
- Inability to provide informed consent (guardian required for minors per Federal Decree-Law No. 4 of 2016 on Medical Liability).
Emergency Red Flags — Seek Immediate Medical Attention:
- Signs of acute CMV disease: severe abdominal pain, acute visual disturbances, or unexplained persistent fever.
- Severe shortness of breath, chest pain, or new-onset confusion in immunocompromised individuals.
- Altered mental status or neurological changes in transplant recipients.
Patient FAQ & Clinical Guidance
1. What is the CMV IGRA test used for and why is it preferred over standard CMV antibody testing?
The CMV IGRA test directly measures your T-cell mediated functional immune response to cytomegalovirus, providing physicians with actionable risk-stratification data for transplant planning and post-transplant immunosuppression management that standard antibody serology cannot deliver. Unlike IgG/IgM tests that only indicate past exposure, the IGRA assay reveals whether your cellular immune system is actively capable of controlling CMV reactivation — making it indispensable for oncologists, nephrologists, and hematologists managing high-risk immunocompromised patients.
2. Do I need to fast or stop medications before the CMV IGRA blood draw?
No fasting or medication cessation is required for the CMV IGRA test; the blood sample must simply be collected in a specific sodium/lithium heparin green-top tube and transported under strict refrigerated cold-chain conditions to our ISO 9001:2015 certified laboratory to ensure 99.9% diagnostic accuracy. You should continue all prescribed immunosuppressive, antiviral, and supportive medications exactly as directed — abrupt discontinuation can precipitate serious clinical deterioration in transplant and oncology patients.
3. How quickly will I receive my CMV IGRA results and who will interpret them?
Your CMV IGRA results are reported the very next day when the sample is collected on Monday or Thursday before 9:00 AM, and comprehensive telephonic post-test clinical guidance is provided by DHA-licensed specialists to help you and your treating physician interpret the findings within your complete clinical picture. The report includes quantitative interferon-gamma values with reference ranges calibrated to international standards, and direct consultation with your ordering oncologist, nephrologist, or hematologist is facilitated to ensure seamless clinical integration.
4. What sample type is required and how is it transported?
A 5 mL (4 mL minimum) whole blood sample collected in one Green Top (Sodium/Lithium Heparin) tube is required. The specimen must be shipped refrigerated at 2–8°C — freezing is strictly prohibited as it compromises cellular integrity and invalidates the IGRA result. Our VIP mobile phlebotomy service ensures temperature-controlled cold-chain transport from your home to our accredited laboratory, with collection available daily from 8 AM to 11 PM.
5. How is the CMV IGRA result interpreted for transplant risk assessment?
A positive CMV IGRA result indicates the presence of functional T-cell mediated immunity against CMV, suggesting a lower risk for post-transplant CMV reactivation. A negative or low-level result in a transplant candidate signals elevated risk and may prompt enhanced prophylactic antiviral strategies or adjusted immunosuppression protocols. Results must always be interpreted in conjunction with CMV viral load, donor/recipient serostatus, and the complete clinical picture by a DHA-licensed specialist.
UAE Regulatory & Data Privacy Adherence
Data Protection & Health Information Governance
- All patient data processed in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL).
- Health information handling adheres to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Clinical testing safety and patient consent governed by Federal Decree-Law No. 4 of 2016 on Medical Liability.
Accreditation & Facility Licensing
- ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139).
- DHA Facility License Number: 1143.
- Laboratory Address: Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
- All testing protocols aligned with international laboratory standards and UAE regulatory requirements.
Clinical & Logistical Metadata
| Test Name | Cytomegalovirus Interferon Gamma Release Assay (CMV IGRA) |
| Price (AED) | 900 AED |
| Turnaround Time | Next-Day Reporting (Mon/Thu by 9 AM) |
| Sample Type / Matrix | 5 mL whole blood (Green Top – Sodium/Lithium Heparin tube). Transport refrigerated at 2–8°C; do not freeze. |
| Methodology Used | Enzyme Immunoassay (ELISA) — Functional T-Cell Response Quantification |
| ICD-10-CM Code | B25.9 |
| LOINC Code | 100963-0 |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
Book Your CMV IGRA Test — Home Collection Available
Insurance verification, pricing inquiries, and appointment scheduling via WhatsApp
+971 54 548 8731دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians